Invivyd (NASDAQ:IVVD – Get Free Report) and Stoke Therapeutics (NASDAQ:STOK – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability and analyst recommendations.
Valuation and Earnings
This table compares Invivyd and Stoke Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Invivyd | $53.43 million | 5.15 | -$52.49 million | ($0.33) | -2.83 |
| Stoke Therapeutics | $184.42 million | 10.00 | -$6.89 million | ($3.34) | -8.56 |
Insider & Institutional Ownership
70.4% of Invivyd shares are owned by institutional investors. 12.2% of Invivyd shares are owned by company insiders. Comparatively, 9.6% of Stoke Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Risk & Volatility
Invivyd has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Comparatively, Stoke Therapeutics has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Invivyd and Stoke Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Invivyd | 1 | 2 | 3 | 0 | 2.33 |
| Stoke Therapeutics | 1 | 0 | 10 | 0 | 2.82 |
Invivyd presently has a consensus price target of $8.00, indicating a potential upside of 757.45%. Stoke Therapeutics has a consensus price target of $44.25, indicating a potential upside of 54.84%. Given Invivyd’s higher probable upside, equities analysts plainly believe Invivyd is more favorable than Stoke Therapeutics.
Profitability
This table compares Invivyd and Stoke Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Invivyd | -183.90% | -59.73% | -48.97% |
| Stoke Therapeutics | -753.60% | -59.36% | -51.46% |
About Invivyd
Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
About Stoke Therapeutics
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Receive News & Ratings for Invivyd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivyd and related companies with MarketBeat.com's FREE daily email newsletter.
